Drug resistance in non-subtype B HIV-1

Journal of Clinical Virology

Volumn 29, Issue 3, 2004, Pages 152-159

  Kantor, Rami ^a   Katzenstein, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug resistance; HIV 1 subtypes; Non B

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; VIRUS GENE; VIRUS ISOLATION; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 1042287077     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(03)00115-X     Document Type: Article

References (90)

1. Adje C., Cheingsong R., Roels T.H., et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J. Acquir. Immune Defic. Syndr. 26:2001;501-506.
2. Balotta C., Facchi G., Violin M., et al. Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J. Acquir. Immune Defic. Syndr. 27:2001;499-505.
3. Barlow K.L., Tatt I.D., Cane P.A., Pillay D., Clewley J.P. Recombinant strains of HIV type 1 in the United Kingdom. AIDS Res. Hum. Retroviruses. 17:2001;467-474.
4. Baxter J.D., Mayers D.L., Wentworth D.N., et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 14:2000;F83-F93.
5. Boden D., Hurley A., Zhang L., et al. HIV-1 drug resistance in newly infected individuals. J. Am. Med. Assoc. 282:1999;1135-1141.
6. Boni J., Pyra H., Gebhardt M., et al. High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland. J. Acquir. Immune Defic. Syndr. 22:1999;174-179.
7. Brindeiro P.A., Brindeiro R.M., Mortensen C., et al. Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy. J. Clin. Microbiol. 40:2002;4512-4519.
8. Brodine S.K., Shaffer R.A., Starkey M.J., et al. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann. Intern. Med. 131:1999;502-506.
9. Cane P.A., de Ruiter A., Rice P.A., Wiselka M., Fox R., Pillay D. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom. J. Clin. Microbiol. 39:2001;2652-2654.
10. Caride E., Brindeiro R., Hertogs K., et al. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART. Virology. 275:2000;107-115.
11. Caride E., Hertogs K., Larder B., et al. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus Genes. 23:2001;193-202.
12. Cingolani A., Antinori A., Rizzo M.G., et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS. 16:2002;369-379.
13. Clavel F., Guetard D., Brun-Vezinet F., et al. Isolation of a new human retrovirus from West African patients with AIDS. Science. 233:1986;343-346.
14. Clevenbergh P., Cua E., Dam E., et al. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naive HIV- infected patients. HIV Clin. Trials. 3:2002;36-44.
15. Cohen C.J., Hunt S., Sension M., et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 16:2002;579-588.
16. Couturier E., Damond F., Roques P., et al. HIV-1 diversity in France, 1996-1998. The AC 11 laboratory network. AIDS. 14:2000;289-296.
17. De Cock K.M., Adjorlolo G., Ekpini E., et al. Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic. J. Am. Med. Assoc. 270:1993;2083-2086.
18. Deeks S.G. Nonnucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. 26:(suppl. 1):2001;S25-S33.
19. DeGruttola V., Dix L., D'Aquila R., et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther. 5:2000;41-48.
20. Deroo S., Robert I., Fontaine E., et al. HIV-1 subtypes in Luxembourg, 1983-2000. AIDS. 16:2002;2461-2467.
21. Descamps D., Apetrei C., Collin G., Damond F., Simon F., Brun-Vezinet F. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors [letter]. AIDS. 12:1998;1109-1111.
22. Durant J., Clevenbergh P., Halfon P., et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 353:1999;2195-2199.
23. Erice A., Mayers D.L., Strike D.G., et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. New Engl. J. Med. 328:1993;1163-1165.
24. Erickson J.W., Gulnik S.V., Markowitz M. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS. 13:(Suppl. A):1999;S189-S204.
25. Fauci A.S., Desrosiers R.C. Pathogenesis of HIV and SIV. Coffin J.M., Hughes S.H., Varmus H.E. Retroviruses. 1997;587-636 Cold Spring Harbor Laboratory Press, New York.
26. Felsenstein J. PHYLIP (Phylogeny Inference Package) Version 3.5. 1993;University of Washington, Seattle.
27. Fonjungo P.N., Dash B.C., Mpoudi E.N., et al. Molecular screening for HIV-1 group N and simian immunodeficiency virus cpz-like virus infections in Cameroon [letter]. AIDS. 14:2000;750-752.
28. Frater A.J., Beardall A., Ariyoshi K., et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS. 15:2001;1493-1502.
29. Gao F., Vidal N., Li Y., et al. Evidence of two distinct subsubtypes within the HIV-1 subtype A radiation. AIDS Res. Hum. Retroviruses. 17:2001;675-688.
30. Garcia-Lerma J.G., Nidtha S., Blumoff K., Weinstock H., Heneine W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc. Natl. Acad. Sci. USA. 98:2001;13907-13912.
31. Goudsmit J., de R.A., de R.E., de B.R. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J. Virol. 71:1997;4479-4484.
32. Grossman Z., Vardinon N., Chemtob D., et al. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS. 15:2001;1453-1460.
33. Gurtler L.G., Hauser P.H., Eberle J., et al. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J. Virol. 68:1994;1581-1585.
34. Hahn B.H., Shaw G.M., De Cock K.M., Sharp P.M. AIDS as a zoonosis: scientific and public health implications. Science. 287:2000;607-614.
35. Hanna G.J., D'Aquila R.T. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin. Infect. Dis. 32:2001;774-782.
36. Haubrich R., Demeter L. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. J. Acquir. Immune Defic. Syndr. 26:(suppl. 1):2001;S51-S59.
37. Haubrich R., Keiser P., Kemper C., et al. CCTG 575: a randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy. Antivir. Ther. 6:2001;63.
38. Hirsch M.S., Brun-Vezinet F., D'Aquila R.T., et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society - USA Panel. J. Am. Med. Assoc. 283:2000;2417-2426.
39. Hizi A., Tal R., Shaharabany M., et al. Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob. Agents Chemother. 37:1993;1037-1042.
40. Holguin A., Aracil B., Alvarez A., Barros C., Soriano V. Prevalence of human immunodeficiency virus type 1 (HIV-1) non-B subtypes in foreigners living in Madrid, Spain, and comparison of the performances of the AMPLICOR HIV-1 MONITOR version 1.0 and the new automated version 1.5. J. Clin. Microbiol. 39:2001;1850-1854.
41. Holguin A., Soriano V. Resistance to antiretroviral agents in individuals with HIV-1 non-B subtypes. HIV Clin. Trials. 3:2002;403-411.
42. Hu D.J., Dondero T.J., Rayfield M.A., et al. The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. J. Am. Med. Assoc. 275:1996;210-216.
43. Irwin K.L., Pau C.P., Lupo D., et al. Presence of human immunodeficiency virus (HIV) type 1 subtype A infection in a New York community with high HIV prevalence: a sentinel site for monitoring HIV genetic diversity in North America. Centers for Disease Control and Prevention-Bronx Lebanon HIV Serosurvey Team. J. Infect. Dis. 176:1997;1629-1633.
44. Jaffe H.W., Schochetman G. Group O human immunodeficiency virus-1 infections. Infect. Dis. Clin. North Am. 12:1998;39-46.
45. Janssens W., Heyndrickx L., Van der Auwera G., et al. Interpatient genetic variability of HIV-1 group O. AIDS. 13:1999;41-48.
46. Kanki P.J., De Cock K.M. Epidemiology and natural history of HIV-2. AIDS. 8:(Suppl. 1):1994;S85-S93.
47. Kantor R., Machekano R., Gonzales M.J., Dupnik B.S., Schapiro J.M., Shafer R.W. Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded model integrating natural language text and sequence analysis. Nucleic Acids Res. 29:2001;296-299.
48. Kantor R., Zijenah L.S., Shafer R.W., et al. HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Res. Hum. Retroviruses. 18:2002;1407-1413.
49. Kantor R., Katzenstein D. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev. 5:2003;25-35.
50. Kaplan A.H., Michael S.F., Wehbie R.S., et al. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc. Natl. Acad. Sci. USA. 91:1994;5597-5601.
51. Korber B., Muldoon M., Theiler J., et al. Timing the ancestor of the HIV-1 pandemic strains. Science. 288:2000;1789-1796.
52. Kuiken C., Foley B., Hahn B., et al. HIV Sequence Compendium 2000. 2000;Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
53. Little S.J., Daar E.S., D'Aquila R.T., et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. J. Am. Med. Assoc. 282:1999;1142-1149.
54. Little S.J., Holte S., Routy J.P., et al. Antiretroviral-drug resistance among patients recently infected with HIV. New Engl. J. Med. 347:2002;385-394.
55. Loveday C. International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. 26:(suppl. 1):2001;S10-S24.
56. Maguire M., Shortino D., Klein A., et al. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob. Agents Chemother. 46:2002;731-738.
57. McCutchan F.E. Understanding the genetic diversity of HIV-1. AIDS. 14:2000;S31-S44.
58. Meynard J.L., Vray M., Morand-Joubert L., et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS. 16:2002;727-736.
59. Miller V. Resistance to protease inhibitors. J. Acquir. Immune Defic. Syndr. 26:(suppl. 1):2001;S34-S50.
60. Nkengasong J., Sylla-Koko F., Peeters M., et al. HIV-1 group O virus infection in Abidjan, Cote d'Ivoire. AIDS. 12:1998;1565-1566.
61. Osmanov S., Pattou C., Walker N., Schwardlander B., Esparza J. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J. Acquir. Immune Defic. Syndr. 29:2002;184-190.
62. Peeters M. The genetic variability of HIV-1 and its implications. Transfus. Clin. Biol. 8:2001;222-225.
63. Peeters M., Sharp P.M. Genetic diversity of HIV-1: the moving target. AIDS. 14:2000;S129-S140.
64. Perez-Alvarez L., Cuevas M.T., Villahermosa M.L., et al. Prevalence of drug resistance mutations in B, non-B subtypes, and recombinant forms of human immunodeficiency virus type 1 in infected individuals in Spain (Galicia). J. Hum. Virol. 4:2001;35-38.
65. Perez-Alvarez L., Thomson M.M., Villahermosa M.L., et al. HIV-1 subtype G and BG recombinant viruses in Spanish natives: evidence of characteristic mutations in reverse transcriptase and protease. AIDS. 15:2001;1907-1910.
66. Pillay D., Walker A.S., Gibb D.M., et al. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the paediatric European network for treatment of AIDS (PENTA) 5 Trial. J. Infect. Dis. 186:2002;617-625.
67. Reeves J.D., Doms R.W. Human immunodeficiency virus type 2. J. Gen. Virol. 83:2002;1253-1265.
68. Ren J., Bird L.E., Chamberlain P.P., Stewart-Jones G.B., Stuart D.I., Stammers D.K. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc. Natl. Acad. Sci. USA. 99:2002;14410-14415.
69. Richman D, Bozzette S, Morton S, et al. The prevalence of antiretroviral drug resistance in the US, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 2001. p. Abstract LB-17.
70. Robertson D.L., Hahn B.H., Sharp P.M. Recombination in AIDS viruses. J. Mol. Evol. 40:1995;249-259.
71. Robertson D.L., Sharp P.M., McCutchan F.E., Hahn B.H. Recombination in HIV-1 [letter]. Nature. 374:1995;124-126.
72. Robertson D.L., Anderson J.L., Bradac J.A., et al. HIV-1 nomenclature proposal a reference guide to HIV-1 classification. Kuiken C.L., Foley B., Hahn B.H., et al. Human Retroviruses and AIDS: a Compilation and Analysis of Nucleic and Amino Acid Sequences. 2000;492-505 Los Alamos National Laboratory, Los Alamos, NM.
73. Robertson D.L., Anderson J.P., Bradac J.A., et al. HIV-1 nomenclature proposal [letter]. Science. 288:2000;55-56.
74. Rubio A., Leal M., Pineda J.A., et al. Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-1-infected antiviral-naive patients from 1989 to 1996. AIDS. 11:1997;1184-1186.
75. Ruibal-Brunet I.J., Cuevas M.T., Diaz-Torres H., et al. Genotypic resistance mutations to antiretroviral drugs in HIV-1 B and non-B subtypes from Cuba. Rev. Panam. Salud. Publica. 10:2001;174-180.
76. Salminen M.O., Carr J.K., Burke D.S., McCutchan F.E. Identification of breakpoints in intergenotypic recombinants of HIV type 1 by bootscanning. AIDS Res. Hum. Retroviruses. 11:1995;1423-1425.
77. Shafer R.W. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 15:2002;247-277.
78. Shafer R.W., Kantor R., Gonzales M.J. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Rev. 2:2000;211-218.
79. Simon F., Mauclere P., Roques P., et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat. Med. 4:1998;1032-1037.
80. Soriano V., de Mendoza C. Genetic mechanisms of resistance to NRTI and NNRTI. HIV Clin. Trials. 3:2002;237-248.
81. Soriano V., de Mendoza C. Genetic mechanisms of resistance to protease inhibitors and entry inhibitors. HIV Clin. Trials. 3:2002;249-257.
82. Thomson M.M., Najera R. Travel and the introduction of human immunodeficiency virus type 1 non- B subtype genetic forms into Western countries. Clin. Infect. Dis. 32:2001;1732-1737.
83. Triques K., Bourgeois A., Vidal N., et al. Near-full-length genome sequencing of divergent African HIV type 1 subtype F viruses leads to the identification of a new HIV type 1 subtype designated K. AIDS Res. Hum. Retroviruses. 16:2000;139-151.
84. Tural C., Ruiz L., Holtzer C., et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 16:2002;209-218.
85. Vanden H.M., Peeters M., Jannes G., et al. Sequence analysis of a highly divergent HIV-1-related lentivirus isolated from a wild captured chimpanzee. Virology. 221:1996;346-350.
86. Vergne L., Malonga-Mouellet G., Mistoul I., et al. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J. Acquir. Immune Defic. Syndr. 29:2002;165-168.
87. Weidle P.J., Malamba S., Mwebaze R., et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet. 360:2002;34-40.
88. Yang G., Song Q., Charles M., Drosopoulos W.C., Arnold E., Prasad V.R. Use of chimeric human immunodeficiency virus types 1 and 2 reverse transcriptases for structure-function analysis and for mapping susceptibility to nonnucleoside inhibitors. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 11:1996;326-333.
89. Yerly S., Rakik A., De Loes S.K., et al. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J. Virol. 72:1998;3520-3523.
90. Yerly S., Kaiser L., Race E., Bru J.P., Clavel F., Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet. 354:1999;729-733.